On 20 June 2024, OPIS issued a press release announcing the good news that, as a result of a partnership we initiated 3 years ago with the non-profit TheraPsil, Health Canada has provided legal access to psilocybin for the first cluster headache patient. Canada now joins Switzerland as one of the few countries where cluster headache patients have been explicitly authorised to use psychedelics outside of clinical trials. We are hopeful that the barriers to access will continue to fall, in Canada and elsewhere, so that all patients with this horrific condition can rapidly and legally access treatment with psychedelics, and also self-administer them if they choose.
The press release is available here as a PDF.